Accessibility, reimbursement and other issues limit uptake of PET/CT among oncologists, survey reveals

Adherence to the National Comprehensive Cancer Network’s (NCCN) PET-adapted guidelines is limited among clinicians treating patients with classic Hodgkin lymphoma (cHL). 

Survey results published in JCO Oncology Practice revealed that although the majority of respondents give significant consideration to NCCN guidelines relative to PET imaging when treating patients, use of the modality during and after treatment cycles for cHL varies among providers. 

Almost all (94%) of the 301 providers surveyed (oncologists, hematologists and hematologists/oncologists) reported obtaining a PET/CT scan at patients’ initial diagnosis; 97% of those providers conduct interim PET/CT for stage 3 and 4 cHL, which is recommended in NCCN guidelines. 

The guidelines suggest using the Deauville five-point scale to review PET/CT results, but the survey results indicated that just 62% of providers adhere to this recommendation. And of those who do, opinions were mixed as to what denotes a positive Deauville five-point scale. 

Although the survey results did not elaborate on factors associated with adherence, some of the data provided by respondents offer hints on the varying usage of PET/CT—the accessibility of the exam could be to blame. 

Difficulty obtaining PET/CT scans was reported by 55% of respondents, with 21% citing this as the greatest barrier in treating cHL. Those who cited accessibility as a hurdle noted that, on average, they were unable to obtain scans on patients 20% of the time. 

Factors associated with difficulty obtaining the exam were divulged as issues with insurance, insufficient reimbursement, PET/CT machines not in close proximity to patients, interpretability and lagging report times. 

Combined, these findings leave much room for improvement, the study authors suggested. 

“These results suggest that there is an opportunity to educate oncologists and radiologists on the importance of consistently reporting PET/CT Deauville 5PS scores and the use of response-adapted imaging to optimize treatment modifications,” the group wrote. 

The survey results are available here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Trimed Popup
Trimed Popup